

BONESUPPORT - Revisiting the Estimates

Redeye revisits its estimates after the Q3'21 report and concludes that certain OPEX assumptions have likely been too conservative and others too optimistic. We have updated our financial models, better reflecting our take on the company's OPEX on all time horizons. The relatively small changes increase our Fair Value Range somewhat.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

BONESUPPORT - Revisiting the Estimates